FPT and De Heus Partner to Elevate Security Operations in High-Tech Agribusiness
25.3.2024 11:06:00 EET | Business Wire | Press release
Global IT corporation FPT and De Heus recently entered a strategic partnership to foster the agriculture giant's security operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320729005/en/
De Heus Vietnam COO Rick van der Linden (L) and FPT Software Europe CEO Tran Van Dung (R) at the signing ceremony attended by senior leaders of the Netherlands government during the economic mission to Vietnam (Photo: Business Wire)
The two firms will join forces to support De Heus’ Security Operations Center, focusing on the scope of Security Information and Event Management (SIEM). Leveraging FPT's prowess in technology and high-quality workforce, this movement will bolster De Heus’ capabilities in terms of system monitoring, security breach detection, and defense measures to effectively mitigate cyber risk and safeguard its information system and security data on a global scale.
The partnership marks a significant milestone for De Heus' digital transformation strategy amid rising cyberattack concerns in the manufacturing and agriculture industries. Both parties expect this to set a solid foundation for future collaborations in other areas like artificial intelligence, machine learning, big data, and more to further advance De Heus' and the agriculture industry's growth.
Tran Van Dung, Chief Executive Officer of FPT Software Europe, said: “While all businesses want to scale their digital transformation initiatives quickly, doing so securely is equally imperative in the face of cyber threats. Leveraging our extensive expertise and demonstrated success in deploying SIEM projects for multinational corporations globally, we stand ready to optimize De Heus' security operations.”
Rick van der Linden, Chief Operating Officer of De Heus Viet Nam, shared: “Through this partnership, FPT and De Heus are committing to leveraging our collective expertise and resources to develop robust security frameworks that will withstand the test of time. Together, we will explore innovative solutions and best practices to enhance cybersecurity measures and protect against emerging threats.”
The signing ceremony was attended by the Netherlands Minister of Infrastructure and Water Management, Mark Harbers; Minister of Agriculture, Nature, and Food Quality, Christianne van der Wal; Chair of the Confederation of Netherlands Industry and Employers, Ingrid Thijssen; and over 140 large enterprises from the Netherlands in pivotal fields of high-tech manufacturing, sustainable agriculture and food production, renewable energy, logistics, and climate adaptation and water.
Established its first office in 2008 in France, FPT has expanded its presence to 16 offices across 9 countries, serving over 70 leading businesses across Europe. Over the past decade, the tech firm has also been actively intensifying its local footprint and delivery capabilities through partnerships and acquisitions ventures, notably with the acquisition of RWE IT Slovakia, a subsidiary of European energy giant RWE in 2014, and the French IT Consulting Firm AOSIS in 2023.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 73,000 employees. For more information, please visit https://fpt.com.vn/en.
About De Heus
De Heus Vietnam, a member of Royal De Heus Group, has been proud to be Vietnam's leading animal feed supplier since 2008. De Heus provides farmers comprehensive nutritional solutions to help improve livestock productivity and product quality. With a team of experienced experts and a modern factory system, De Heus is committed to providing high-quality animal feed for all types of animals, from livestock, poultry, and aquaculture to pets. De Heus' reputable brands, such as De Heus, Windmill, Koudijs, Con Cò, and Anco, have become familiar to Vietnamese farmers. De Heus always accompanies Vietnamese farmers, aiming towards developing a sustainable and prosperous agriculture.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320729005/en/
Contact information
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom